Overview - CytoKinetics $CYTK is developing first-in-class muscle activators to treat muscle debilitation. Drug candidates currently in clinical development are skeletal muscle activators tirasemtiv and CK-2127107, and cardiac muscle activator omecamtiv mecarbil.

*** L3 or above subscription required to read the rest of the article ... Login or Subscribe/Upgrade here